KAREN BORGOY
Prescription History 1871891663
Nurse Practitioner in Keizer, OR
Medicare Part D Prescription History
Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for KAREN BORGOY, an active Nurse Practitioner specialist practicing in Keizer, OR. Our medical registry currently tracks 2 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 57 documented patient claims. Among these therapy options, the most frequently utilized medication is Albuterol Sulfate Hfa, which accounts for 41 claims alone. Use the table below to sort by claims, cost, or utilization compared with the state average; select any medication for its full profile.
| Medication | Prescriptions (2023)Rx (2023) | Avg Cost per FillCost / Fill | Vs. Other OR PrescribersVs. OR Avg |
|---|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 41 | $21.09▼ below OR avg | ≈ Typical |
About Albuterol Sulfate Hfa: Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. Show more ▾ It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol. In 2023, this provider wrote 41 Medicare prescriptions for Albuterol Sulfate Hfa, about 82% of the volume of the typical Oregon prescriber of this medication (50). Medicare paid an average of $21.09 per fill, versus $46.71 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average OR prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the OR average for this medication. 41 30-Day Fills standardized to 30-day supplies 1,186 Days of Medication total across all patients in 2023 | |||
| Paxlovid (Eua)Nirmatrelvir/Ritonavir | 16 | $17.00 | ≈ Typical |
About Paxlovid (Eua): The combination of nirmatrelvir tablets and ritonavir tablets is a product that the FDA is allowing to be given for emergency use to treat COVID-19. Show more ▾ The product is also approved to be used in Canada to treat COVID-19. It is used by people who have recently tested positive for coronavirus, have had mild to moderate symptoms for no more than 5 days and are not hospitalized. To receive this product you must also be at high risk for COVID-19 complications due to older age, obesity, or ongoing medical conditions (such as lung or heart disease or diabetes, among others). Talk to your doctor about the risks and benefits of treatment with nirmatrelvir and ritonavir. Nirmatrelvir is a SARS-CoV-2 main protease inhibitor. It works by preventing the growth of the virus that causes COVID-19. Ritonavir increases (boosts) the levels of nirmatrelvir. This helps nirmatrelvir work better. More information about nirmatrelvir and ritonavir is available from the FDA Fact Sheet for Patients, Parents, and Caregivers for Emergency Use and from the Health Canada Patient Medication Information sheet. There is limited information about how safe and effective the combination of nirmatrelvir and ritonavir is for treating COVID-19. Study results show that nirmatrelvir and ritonavir may help people who have recently tested positive for coronavirus stay out of the hospital. This product is not for use by people who are hospitalized due to COVID-19. The information in this document reflects emerging data, which is evolving and subject to reassessment. Users should be aware of these considerations in their review of nirmatrelvir and ritonavir, and it is always the responsibility of treating practitioners to exercise independent judgement in making care decisions. In 2023, this provider wrote 16 Medicare prescriptions for Paxlovid (Eua), about 76% of the volume of the typical Oregon prescriber of this medication (21). Medicare paid an average of $17.00 per fill, versus $10.86 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average OR prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 16 30-Day Fills standardized to 30-day supplies 80 Days of Medication total across all patients in 2023 | |||
About this data. The prescription history for KAREN BORGOY is compiled from the Centers for Medicare & Medicaid Services (CMS) Medicare Part D Prescriber Public Use File for calendar year 2023, the most recent federal release. Figures cover prescriptions filled for Medicare Part D beneficiaries only; prescriptions under private insurance, Medicaid, or self-pay plans are not included. Because prescribing decisions are generally consistent across coverage types, this record offers a useful view of the overall Nurse Practitioner prescribing approach at this Keizer, OR practice.
Reading the costs. Drug costs are gross amounts paid to pharmacies under Part D, including both plan and beneficiary payments. They are not the price a patient pays at the pharmacy counter. Medications with fewer than 11 claims are excluded from the federal source data, and state comparisons use the average volume among OR prescribers of the same medication. Always confirm current medications and costs directly with the provider and your plan.
